Ultragenyx Pharmaceutical Inc (RARE) investors sentiment decreased to 1.01 in Q4 2018. It’s down -0.14, from 1.15 in 2018Q3. The ratio worsened, as 73 investment managers increased or opened new equity positions, while 72 sold and decreased their stock positions in Ultragenyx Pharmaceutical Inc. The investment managers in our database now possess: 49.53 million shares, up from 48.78 million shares in 2018Q3. Also, the number of investment managers holding Ultragenyx Pharmaceutical Inc in top ten equity positions decreased from 1 to 0 for a decrease of 1. Sold All: 27 Reduced: 45 Increased: 49 New Position: 24.
The stock of XBiotech Inc. (NASDAQ:XBIT) is a huge mover today! The stock decreased 1.80% or $0.18 during the last trading session, reaching $9.8. About 91,612 shares traded. XBiotech Inc. (NASDAQ:XBIT) has risen 90.53% since March 13, 2018 and is uptrending. It has outperformed by 86.16% the S&P500. Some Historical XBIT News: 16/04/2018 – XBIOTECH INC – CO WOULD EVALUATE A NEW SUBCUTANEOUS FORMULATION OF CO’S TRUE HUMAN MONOCLONAL ANTIBODY, MABP1, IN TWO SEPARATE PHASE 2 STUDIES; 02/04/2018 – XBIOTECH INC – OBTAINED AN EXCLUSIVE, WORLDWIDE LICENSE FROM CT ATLANTIC AG, A SWISS BIOTECHNOLOGY COMPANY; 16/04/2018 – XBIOTECH INC – UPCOMING PHASE 2 CLINICAL STUDIES IN PATIENTS WITH MODERATE TO SEVERE ATOPIC DERMATITIS (AD) AND HIDRADENITIS SUPPURATIVA (HS); 02/04/2018 – XBIOTECH INC – HAS OBTAINED AN EXCLUSIVE, WORLDWIDE LICENSE FROM CT ATLANTIC AG; 02/04/2018 XBiotech In-licenses Anti-NY-ESO-1 Antibody Targeting Advanced Cancer; 22/05/2018 – XBiotech Announces First Patient in Phase 2 Study Evaluating MABp1 in Patients with Atopic Dermatitis; 02/04/2018 – XBIOTECH – WILL USE ITS TECHNOLOGY TO ADVANCE DEVELOPMENT OF TRUE HUMAN(TM )ANTI-NY-ESO-1 MONOCLONAL ANTIBODY, 12D7; 16/04/2018 – Press Release: XBiotech Announces Upcoming Phase 2 Clinical Studies in Dermatology; 16/04/2018 – XBiotech Announces Upcoming Phase 2 Clinical Studies in Dermatology; 16/04/2018 – XBIOTECH INC – CONDUCTING FINAL PREPARATIONS FOR STUDY LAUNCH INCLUDING FIRST CLINICAL SITE INITIATION SCHEDULED LATER THIS MONTHThe move comes after 7 months negative chart setup for the $351.03M company. It was reported on Mar, 13 by Barchart.com. We have $9.31 PT which if reached, will make NASDAQ:XBIT worth $17.55 million less.
More notable recent Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) news were published by: Nasdaq.com which released: “China becomes world’s biggest importer of rare earths – Nasdaq” on March 13, 2019, also Nasdaq.com with their article: “Dow Lags as Boeing’s Troubles Intensify – Nasdaq” published on March 12, 2019, Nasdaq.com published: “RARE Makes Bullish Cross Above Critical Moving Average – Nasdaq” on March 01, 2019. More interesting news about Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) were released by: Nasdaq.com and their article: “In rare move, U.S. judge orders acquittal of Barclays currency trader – Nasdaq” published on March 04, 2019 as well as Nasdaq.com‘s news article titled: “Why BB&T (BBT) is a Top Dividend Stock for Your Portfolio – Nasdaq” with publication date: March 13, 2019.
Ultragenyx Pharmaceutical Inc., a clinical-stage biopharmaceutical company, focuses on the identification, acquisition, development, and commercialization of various products for the treatment of rare and ultra-rare genetic diseases in the United States. The company has market cap of $3.84 billion. The firm is developing various biologics product candidates, including KRN23, a human monoclonal antibody that in Phase III adult study to bind and reduce the biological activity of fibroblast growth factor 23 to enhance abnormally low phosphate levels in patients with X-linked hypophosphatemia, as well as for the treatment of tumor-induced osteomalacia. It currently has negative earnings. The Company’s biologics product candidates also comprise recombinant human beta -glucuronidase , an enzyme replacement therapy, which completed the Phase 3 clinical study for the treatment of mucopolysaccharidosis 7; and recombinant human protective protein cathepsin-A (rhPPCA), an enzyme replacement therapy, which is in preclinical development for galactosialidosis.
Analysts await Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) to report earnings on May, 6. They expect $-1.75 earnings per share, down 382.26% or $2.37 from last year’s $0.62 per share. After $-1.73 actual earnings per share reported by Ultragenyx Pharmaceutical Inc. for the previous quarter, Wall Street now forecasts 1.16% negative EPS growth.
Abingworth Llp holds 1.5% of its portfolio in Ultragenyx Pharmaceutical Inc. for 38,100 shares. Highline Capital Management L.P. owns 458,513 shares or 1.34% of their US portfolio. Moreover, Rock Springs Capital Management Lp has 0.87% invested in the company for 425,000 shares. The New York-based Opus Point Partners Management Llc has invested 0.51% in the stock. Verity Asset Management Inc., a North Carolina-based fund reported 7,581 shares.
The stock increased 1.28% or $0.85 during the last trading session, reaching $67.2. About 165,043 shares traded. Ultragenyx Pharmaceutical Inc. (RARE) has risen 36.36% since March 13, 2018 and is uptrending. It has outperformed by 31.99% the S&P500. Some Historical RARE News: 30/05/2018 – Rentschler Fill Solutions and Ultragenyx Start Fill & Finish Collaboration for the US Commercial Supply of Drug Product; 07/03/2018 – Ultragenyx Says Three Patients In Phase 1/2 Gene Therapy Study Had Positive Results — MarketWatch; 17/04/2018 – FDA approves Ultragenyx’s treatment for rare type of rickets; 30/04/2018 – ULTRAGENYX & KYOWA KIRIN REPORT CRYSVITA® (BUROSUMAB-TWZA) NOW; 23/04/2018 – Ultragenyx Announces Filing and FDA Clearance of an Investigational New Drug Application for DTX401, a Gene Therapy for the Tre; 23/04/2018 – Ultragenyx Announces Filing and FDA Clearance of an Investigational New Drug Application for DTX401, a Gene Therapy for the Treatment of Glycogen Storage Disease Type la; 17/04/2018 – FDA: Biologic License Application (BLA): 761068 Company: ULTRAGENYX PHARM INC; 17/04/2018 – U.S. FDA SAYS GRANTED APPROVAL OF CRYSVITA TO ULTRAGENYX PHARMACEUTICAL INC; 30/05/2018 – Rentschler Fill Solutions and Ultragenyx start fill & finish collaboration for the US commercial supply of drug product Mepsevii; 17/04/2018 – Ultragenyx and Kyowa Kirin Announce FDA Approval of Crysvita® (burosumab-twza) for the Treatment of Children and Adults with X
More important recent XBiotech Inc. (NASDAQ:XBIT) news were published by: Seekingalpha.com which released: “XBiotech up 4% premarket on positive bermekimab data – Seeking Alpha” on March 05, 2019, also Seekingalpha.com published article titled: “XBiotech up 13% on positive bermekimab data – Seeking Alpha”, Streetinsider.com published: “XBiotech (XBIT) Says Results from Phase 2 Clinical Trial of Bermekimab in Treatment of Atopic Dermatitis to be Presented at ADD – StreetInsider.com” on March 01, 2019. More interesting news about XBiotech Inc. (NASDAQ:XBIT) was released by: Seekingalpha.com and their article: “Key events next week – healthcare – Seeking Alpha” with publication date: February 22, 2019.
XBiotech Inc., a clinical-stage biopharmaceutical company, engages in discovering and developing True Human monoclonal antibodies for treating various diseases. The company has market cap of $351.03 million. The companyÂ’s lead product is Xilonix, which is also known as MABp1, a therapeutic antibody that neutralizes interleukin-1 alpha, which has completed Phase III clinical trial in Europe for the treatment of symptomatic and advanced colorectal cancer. It currently has negative earnings. It has also investigating its lead product candidate in various clinical trials for other inflammatory conditions, including vascular disease, type II diabetes, acne, psoriasis, pyoderma gangrenosum, and hidradenitis suppurativa, as well as staphylococcus aureus infection, influenza, and clostridium difficile infection diseases.
Receive News & Ratings Via Email – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings with our FREE daily email newsletter.